1
|
Broeckling CD, Beger RD, Cheng LL, Cumeras R, Cuthbertson DJ, Dasari S, Davis WC, Dunn WB, Evans AM, Fernández-Ochoa A, Gika H, Goodacre R, Goodman KD, Gouveia GJ, Hsu PC, Kirwan JA, Kodra D, Kuligowski J, Lan RSL, Monge M, Moussa LW, Nair SG, Reisdorph N, Sherrod SD, Ulmer Holland C, Vuckovic D, Yu LR, Zhang B, Theodoridis G, Mosley JD. Current Practices in LC-MS Untargeted Metabolomics: A Scoping Review on the Use of Pooled Quality Control Samples. Anal Chem 2023; 95:18645-18654. [PMID: 38055671 PMCID: PMC10753522 DOI: 10.1021/acs.analchem.3c02924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 11/02/2023] [Accepted: 11/10/2023] [Indexed: 12/08/2023]
Abstract
Untargeted metabolomics is an analytical approach with numerous applications serving as an effective metabolic phenotyping platform to characterize small molecules within a biological system. Data quality can be challenging to evaluate and demonstrate in metabolomics experiments. This has driven the use of pooled quality control (QC) samples for monitoring and, if necessary, correcting for analytical variance introduced during sample preparation and data acquisition stages. Described herein is a scoping literature review detailing the use of pooled QC samples in published untargeted liquid chromatography-mass spectrometry (LC-MS) based metabolomics studies. A literature query was performed, the list of papers was filtered, and suitable articles were randomly sampled. In total, 109 papers were each reviewed by at least five reviewers, answering predefined questions surrounding the use of pooled quality control samples. The results of the review indicate that use of pooled QC samples has been relatively widely adopted by the metabolomics community and that it is used at a similar frequency across biological taxa and sample types in both small- and large-scale studies. However, while many studies generated and analyzed pooled QC samples, relatively few reported the use of pooled QC samples to improve data quality. This demonstrates a clear opportunity for the field to more frequently utilize pooled QC samples for quality reporting, feature filtering, analytical drift correction, and metabolite annotation. Additionally, our survey approach enabled us to assess the ambiguity in the reporting of the methods used to describe the generation and use of pooled QC samples. This analysis indicates that many details of the QC framework are missing or unclear, limiting the reader's ability to determine which QC steps have been taken. Collectively, these results capture the current state of pooled QC sample usage and highlight existing strengths and deficiencies as they are applied in untargeted LC-MS metabolomics.
Collapse
Affiliation(s)
- Corey D. Broeckling
- Analytical
Resources Core: Bioanalysis and Omics Center; Department of Agricultural
Biology, Colorado State University, Fort Collins, Colorado 80525, United States
| | - Richard D. Beger
- Division
of Systems Biology, National Center for
Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas 72079, United States
| | - Leo L. Cheng
- Departments
of Radiology and Pathology, Massachusetts
General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Raquel Cumeras
- Department
of Oncology, Hospital Universitari Sant Joan de Reus, Institut d’Investigació Sanitària Pere Virgili
(IISPV), URV, CERCA, 43204 Reus, Spain
| | - Daniel J. Cuthbertson
- Agilent
Technologies Inc., 5301 Stevens Creek Blvd, Santa Clara, California 95051, United States
| | - Surendra Dasari
- Department
of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota 55905, United States
| | - W. Clay Davis
- National
Institute of Standards and Technology, Chemical
Sciences Division, 331
Fort Johnson Road, Charleston, South Carolina 29412, United States
| | - Warwick B. Dunn
- Centre
for Metabolomics Research, Department of Biochemistry and Systems
Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, BioSciences Building, Crown St., Liverpool L69 7ZB,U.K.
| | - Anne Marie Evans
- Metabolon,
Inc. 617 Davis Drive, Suite 100, Morrisville, North Carolina 27560, United States
| | | | - Helen Gika
- School
of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
| | - Royston Goodacre
- Centre
for Metabolomics Research, Department of Biochemistry and Systems
Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, BioSciences Building, Crown St., Liverpool L69 7ZB,U.K.
| | - Kelli D. Goodman
- Metabolon, Inc., 617 Davis Drive, Suite 100, Morrisville, North Carolina 27560, United States
| | - Goncalo J. Gouveia
- Institute for Bioscience
and Biotechnology Research, National Institute
of Standards and Technology, University
of Maryland, Gudelsky
Drive, Rockville, Maryland 20850, United States
| | - Ping-Ching Hsu
- Department
of Environmental Health Sciences, University
of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7190, United States
| | - Jennifer A. Kirwan
- Metabolomics, Berlin Institute of Health at Charite, Anna-Louisa-Karsch-Str. 2, 10178 Berlin, Germany
| | - Dritan Kodra
- Department
of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
| | - Julia Kuligowski
- Neonatal
Research Group, Health Research Institute
La Fe, Avenida Fernando
Abril Martorell 106, 46026 Valencia, Spain
| | - Renny Shang-Lun Lan
- Arkansas Children’s Nutrition Center, Little Rock, Arkansas 72202-3591, United States
| | - María
Eugenia Monge
- Centro
de Investigaciones en Bionanociencias (CIBION), Consejo Nacional de Investigaciones Científicas y Técnicas
(CONICET), Godoy Cruz
2390, C1425FQD Ciudad
de Buenos Aires, Argentina
| | - Laura W. Moussa
- Center
for Veterinary Medicine, Office of New Animal Drug Evaluation, U.S. Food and Drug Administration, Rockville, Maryland 20855, United States
| | - Sindhu G. Nair
- Department
of Biological Sciences, University of Alberta, Edmonton, AB T6G 2G2, Canada
| | - Nichole Reisdorph
- Department
of Pharmaceutical Sciences, University of
Colorado−Anschutz Medical Campus, Aurora, Colorado 80045, United States
| | - Stacy D. Sherrod
- Department
of Chemistry and Center for Innovative Technology, Vanderbilt University, Nashville, Tennessee 37240, United States
| | - Candice Ulmer Holland
- Chemistry
Branch, Eastern Laboratory, Office of Public
Health Science, USDA-FSIS, Athens, Georgia 30605, United States
| | - Dajana Vuckovic
- Department
of Chemistry and Biochemistry, Concordia
University, 7141 Sherbrooke
Street West, Montreal, QC H4B 1R6, Canada
| | - Li-Rong Yu
- Division
of Systems Biology, National Center for
Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas 72079, United States
| | - Bo Zhang
- Olaris, Inc., 175 Crossing
Blvd Suite 410, Framingham, Massachusetts 01702, United States
| | - Georgios Theodoridis
- Department
of Chemistry, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece
| | - Jonathan D. Mosley
- Center
for Environmental Measurement and Modeling, Environmental Protection Agency, Athens, Georgia 30605, United States
| |
Collapse
|
2
|
Mundt KA, Dell LD, Boffetta P, Beckett EM, Lynch HN, Desai VJ, Lin CK, Thompson WJ. The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens. BMC Cancer 2021; 21:227. [PMID: 33676443 PMCID: PMC7936449 DOI: 10.1186/s12885-021-07908-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 02/12/2021] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Although myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) - including chronic myeloid leukemia (CML) - and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are largely clinically distinct myeloid malignancies, epidemiological studies rarely examine them separately and often combine them with lymphoid malignancies, limiting possible etiological interpretations for specific myeloid malignancies. METHODS We systematically evaluated the epidemiological literature on the four chemical agents (1,3-butadiene, formaldehyde, benzene, and tobacco smoking, excluding pharmaceutical, microbial and radioactive agents, and pesticides) classified by the International Agency for Research on Cancer as having sufficient epidemiological evidence to conclude that each causes "myeloid malignancies." Literature searches of IARC Monographs and PubMed identified 85 studies that we critically assessed, and for appropriate subsets, summarized results using meta-analysis. RESULTS Only two epidemiological studies on 1,3-butadiene were identified, but reported findings were inadequate to evaluate specific myeloid malignancies. Studies on formaldehyde reported results for AML and CML - and not for MDS or MPN - but reported no increased risks. For benzene, several specific myeloid malignancies were evaluated, with consistent associations reported with AML and MDS and mixed results for CML. Studies of tobacco smoking examined all major myeloid malignancies, demonstrating consistent relationships with AML, MDS and MPN, but not with CML. CONCLUSIONS Surprisingly few epidemiological studies present results for specific myeloid malignancies, and those identified were inconsistent across studies of the same exposure, as well as across chemical agents. This exercise illustrates that even for agents classified as having sufficient evidence of causing "myeloid malignancies," the epidemiological evidence for specific myeloid malignancies is generally limited and inconsistent. Future epidemiological studies should report findings for the specific myeloid malignancies, as combining them post hoc - where appropriate - always remains possible, whereas disaggregation may not. Furthermore, combining results across possibly discrete diseases reduces the chances of identifying important malignancy-specific causal associations.
Collapse
Affiliation(s)
| | - L D Dell
- Ramboll US Consulting Inc., Amherst, MA, USA
| | - P Boffetta
- Stony Brook Cancer Center, Stony Brook, NY, USA
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
| | | | | | - V J Desai
- Mount Sinai Hospital, New York, NY, USA
| | - C K Lin
- Cardno ChemRisk, Boston, MA, USA
| | | |
Collapse
|